Amyris (AMRS) – StreetInsider.com Reports
-
Amyris (AMRSQ) Terminates 220 Employees, Sees $2.4M Charge
-
Amyris (AMRS) Announces Operational and Financial Restructuring
-
Amyris (AMRS) Announces Ceo Transition And Global Reduction In Force
-
Amyris (AMRS) Secures New Funding, Announces Strategic Transformation
-
Jefferies Downgrades Amyris, Inc. (AMRS) to Hold, 'Moves to Fix Liquidity Likely Pull Value from 2024–28'
-
Amyris (AMRS) Misses Q1 EPS by 20c
-
Canaccord Genuity Starts Amyris, Inc. (AMRS) at Buy
-
Amyris, Inc. (AMRS) PT Lowered to $0.80 at Roth/MKM
-
Amyris (AMRS) Reports Q1 Revenue of $56M
-
Amyris, Inc. (AMRS) PT Lowered to $4 at TD Cowen
-
Amyris, Inc. (AMRS) PT Lowered to $5 at H.C. Wainwright
-
Amyris, Inc. (AMRS) PT Lowered to $1.50 at Piper Sandler
-
Amyris (AMRS) Misses Q4 EPS by 22c
-
Amyris (AMRS) Sells Certain Cosmetic Ingredients to Givaudan
-
Amyris (AMRS) launches 4U by Tia exclusively at Walmart
-
Amyris, Inc. (AMRS) PT Lowered to $2 at Piper Sandler
-
Amyris (AMRS) Prices $50M Direct Offering and Private Placement at $1.50/sh
-
Increasing unusual put option volume: GOTU LUV AMRS APO
-
Amyris (AMRS) Advances Strategic Transaction
-
UPDATE: JPMorgan Downgrades Amyris, Inc. (AMRS) to Underweight
-
Amyris, Inc. (AMRS) PT Lowered to $6 at Cowen
-
Amyris, Inc. (AMRS) PT Lowered to $2.50 at Piper Sandler
-
Oppenheimer Downgrades Amyris, Inc. (AMRS) to Perform
-
Amyris (AMRS) Misses Q3 EPS by 42c
-
Amyris (AMRS) Brands Expanding in UK and Europe. Executing on continued accelerated growth and lower costs
-
Amyris, Inc. (AMRS) PT Raised to $4 at Piper Sandler
-
Increasing unusual put option volume: AMRS FAST ABC YANG LC ISEE
-
Roth Capital Downgrades Amyris, Inc. (AMRS) to Neutral
-
Amyris (AMRS) Misses Q2 EPS by 5c
-
JPMorgan Starts Amyris, Inc. (AMRS) at Neutral
-
Increasing unusual put option volume: AMRS VTI VMW NTNX UA WSM MDT
-
UPDATE: Piper Sandler Starts Amyris, Inc. (AMRS) at Neutral
-
Amyris (AMRS) Misses Q1 EPS by 7c
-
Amyris, Inc. (AMRS) PT Lowered to $22 at Oppenheimer
-
Cowen Assumes Amyris, Inc. (AMRS) at Outperform
-
Amyris (AMRS) Reports Q4 EPS of ($0.33)
-
Amyris, Inc. (AMRS) PT Lowered to $8 at Roth Capital
-
Amyris (AMRS) Appoints Ana Dutra to its Board
-
Amyris (AMRS) Acquires Menolabs
-
Amyris, Inc. (AMRS) PT Lowered to $12 at Jefferies
-
Amyris (AMRS) Misses Q3 EPS by 27c
-
Cowen Assumes Amyris, Inc. (AMRS) at Outperform
-
Amyris (AMRS) Acquires MG Empower
-
Amyris (AMRS) Announces Promising In-Vivo Results For Intranasal Delivery Of RNA/NLC COVID-19 Vaccine
-
Amyris, Inc. (AMRS) PT Raised to $26 at Oppenheimer
-
Amyris (AMRS) Misses Q2 EPS by 2c
-
Amyris, Inc. (AMRS) PT Raised to $19 at Cowen
-
Amyris (AMRS) Announces Acquisition of OLIKA Consumer Brand
-
UPDATE: HSBC Starts Amyris, Inc. (AMRS) at Buy
-
Amyris, Inc. (AMRS) PT Lowered to $25 at Roth Capital
Back to AMRS Stock Lookup